{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T22:25:55Z","timestamp":1788474355535,"version":"build-2803163510"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2023,2,22]],"date-time":"2023-02-22T00:00:00Z","timestamp":1677024000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,22]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Lascufloxacin hydrochloride (LSFX) is a quinolone antibiotic that inhibits DNA gyrase and topoisomerase IV of bacteria, it is anticipated to minimize antibiotic resistance in bacteria. It exhibits antibacterial activity against a relatively wide range of bacterial species, including anaerobic bacteria, and its efficacy and safety against community-acquired pneumonia have been shown; however, its efficacy and safety against nursing and healthcare associated pneumonia (NHCAP) have not been verified.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods\/Design:<\/jats:title>\n            <jats:p>Here, a single-arm, open-label, uncontrolled study was conducted in which LSFX was administered to patients with NHCAP at 24 facilities. The research subjects (77 cases) were orally administered 75\u2009mg of LSFX once a day for 7 days. The primary endpoint was the clinical efficacy at the time of test of cure (TOC) (TOC; 5\u201310 days after the end of LSFX administration), while the secondary endpoints were the efficacy at the time of end of treatment, early clinical efficacy, microbiological efficacy at the time of TOC and end of treatment, and safety evaluation of LSFX.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Discussion:<\/jats:title>\n            <jats:p>NHCAP is a common pneumonia in clinical settings and a notable pneumonia whose mortality is high compared to community-acquired pneumonia. The present study showed the efficacy and safety of LSFX against NHCAP, which could lead to a larger number of therapeutic options for NHCAP.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000033092","type":"journal-article","created":{"date-parts":[[2023,2,24]],"date-time":"2023-02-24T12:04:20Z","timestamp":1677240260000},"page":"e33092","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Evaluation of efficacy and safety of lascufloxacin for nursing and healthcare associated pneumonia: single-arm, open-label clinical trial: A study protocol"],"prefix":"10.1097","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3229-2277","authenticated-orcid":false,"given":"Naoki","family":"Hosogaya","sequence":"first","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"},{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Takazono","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"},{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Ota","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Kiya","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumi","family":"Shirai","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rina","family":"Kawasaki","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yano","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinpei","family":"Morimoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rumiko","family":"Nakao","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumiko","family":"Kanamaru","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Medical affairs, KYORIN Pharmaceutical Co.,Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Medical affairs, KYORIN Pharmaceutical Co.,Ltd., Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chizu","family":"Fukushima","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Clinical Research Center, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Mukae","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Nagasaki University Hospital, Nagasaki, Japan"},{"name":"Department of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R3-20250805","doi-asserted-by":"crossref","first-page":"e00120","DOI":"10.1128\/AAC.00120-17","article-title":"In vitro activities and spectrum of the novel fluoroquinolone lascufloxacin (KRP-AM1977).","volume":"61","author":"Kishii","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.anaerobe.2018.08.002","article-title":"In vitro activity of lascufloxacin, a novel fluoroquinolone antibacterial agent, against various clinical isolates of anaerobes and Streptococcus anginosus group.","volume":"54","author":"Yamagishi","year":"2018","journal-title":"Anaerobe"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1128\/AAC.45.6.1649-1653.2001","article-title":"Contributions of the 8-methoxy group of Gatifloxacin to resistance selectivity, target preference, and antibacterial activity against Streptococcus Penumonae.","volume":"45","author":"Fukuda","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"R6-20250805","doi-asserted-by":"crossref","first-page":"e01971","DOI":"10.1128\/AAC.01971-17","article-title":"In vitro activity of lascufloxacin against Streptococcus pneumoniae with mutations in the quinolone resistance-determining regions.","volume":"62","author":"Murata","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"R7-20250805","first-page":"41","article-title":"Phase III double-blind comparative study of lascufloxacin versus Levofloxacin in patients with community-acquired pneumonia.","volume":"68","author":"Miki","year":"2020","journal-title":"J Infect Chemother"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"200","DOI":"10.7326\/0003-4819-158-3-201302050-00583","article-title":"SPIRIT 2013 statement: Defining standard protocol items for clinical trials.","volume":"158","author":"Chan","year":"2013","journal-title":"Ann Intern Med"},{"key":"R9-20250805","first-page":"c332","article-title":"CONSORT 2010 statement: Updated guidelines for reporting parallel group randomised trials.","volume":"340","author":"Schulz","year":"2010","journal-title":"BMC Medicine"},{"key":"R10-20250805","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","year":"2013","journal-title":"JAMA"},{"key":"R12-20250805","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2169\/internalmedicine.45.1691","article-title":"The JRS guidelines for the management of community-acquired pneumonia in adults: an update and new recommendations.","volume":"45","author":"Miyashita","year":"2006","journal-title":"Intern Med"},{"key":"R13-20250805","doi-asserted-by":"crossref","first-page":"P1717","DOI":"10.1093\/ageing\/22.suppl_2.P17-b","article-title":"Detection and management of dysphagia in patients with acute stroke.","volume":"22","author":"Ellul","year":"1993","journal-title":"Age Ageing"},{"key":"R14-20250805","doi-asserted-by":"crossref","first-page":"e63103","DOI":"10.1371\/journal.pone.0063103","article-title":"Significance of anaerobes and oral bacteria in community-acquired pneumonia.","volume":"8","author":"Yamazaki","year":"2013","journal-title":"PLoS One"},{"key":"R15-20250805","first-page":"283","article-title":"Efficacy and safety of moxifloxacin in patients with nursing and healthcare associated pneumonia.","volume":"66","author":"Yamasaki","year":"2013","journal-title":"Jpn J Antibiot"},{"key":"R18-20250805","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1378\/chest.10-0460","article-title":"A higher significance of anaerobes: the clone library analysis of bacterial pleurisy.","volume":"139","author":"Kawanami","year":"2011","journal-title":"Chest"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033092","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T20:11:51Z","timestamp":1754424711000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000033092"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,22]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000033092","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,22]]}}}